756 related articles for article (PubMed ID: 25629890)
1. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
2. Evolution of empiric vancomycin dosing in a neonatal population.
Radu L; Bengry T; Akierman A; Alshaikh B; Yusuf K; Dersch-Mills D
J Perinatol; 2018 Dec; 38(12):1702-1707. PubMed ID: 30341404
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of vancomycin target trough attainment with published dosing regimens in the neonatal intensive care unit population.
Chung E; Lee SE; Abraham T; Saad NN; Gad A
J Neonatal Perinatal Med; 2019; 12(1):21-27. PubMed ID: 30149480
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the vancomycin dosage regimen based on serum creatinine used in the neonatal intensive care unit.
Irikura M; Fujiyama A; Saita F; Fukushima S; Kitaoka H; Fukuda T; Kawase A; Kondo Y; Ishitsuka Y; Kondo G; Maeda T; Yukawa E; Irie T
Pediatr Int; 2011 Dec; 53(6):1038-44. PubMed ID: 21810150
[TBL] [Abstract][Full Text] [Related]
5. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin is commonly under-dosed in critically ill children and neonates.
Sosnin N; Curtis N; Cranswick N; Chiletti R; Gwee A
Br J Clin Pharmacol; 2019 Nov; 85(11):2591-2598. PubMed ID: 31378957
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations.
Reilly AM; Ding MX; Rower JE; Kiser TH
J Clin Pharmacol; 2019 Jul; 59(7):997-1005. PubMed ID: 30776089
[TBL] [Abstract][Full Text] [Related]
8. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
Villanueva RD; Talledo O; Neely S; White B; Celii A; Cross A; Kennedy R
J Trauma Acute Care Surg; 2019 Nov; 87(5):1164-1171. PubMed ID: 31464871
[TBL] [Abstract][Full Text] [Related]
10. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment.
Hong J; Krop LC; Johns T; Pai MP
Pharmacotherapy; 2015 May; 35(5):455-63. PubMed ID: 26011138
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
14. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.
Hall RG; Hazlewood KA; Brouse SD; Giuliano CA; Haase KK; Frei CR; Forcade NA; Bell T; Bedimo RJ; Alvarez CA
BMC Pharmacol Toxicol; 2013 Feb; 14():12. PubMed ID: 23402420
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
16. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
Thomas CA; Picone A; Menon S; Willis BC
Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
[TBL] [Abstract][Full Text] [Related]
17. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
18. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ
Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452
[TBL] [Abstract][Full Text] [Related]
19. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
20. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]